Ani Pharmaceuticals (ANIP) Non Operating Income (2012 - 2026)

Ani Pharmaceuticals has disclosed Non Operating Income across 15 years of filings, most recently posting -$651000.0 for Q1 2026.

• Non Operating Income for Q1 2026 came in at -$651000.0, down 428.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (up 128.53% YoY), and the FY2025 annual result was $1.9 million, up 147.95% from the prior year.
• Non Operating Income came in at -$651000.0 for Q1 2026 at Ani Pharmaceuticals, down from $850000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $1.7 million in Q2 2025 to a low of -$2.5 million in Q3 2024.
• The 5-year median for Non Operating Income is -$39000.0 (2023), against an average of -$131705.9.
• Across the five-year window, Non Operating Income slumped 6400.0% in 2024 and surged 2076.14% in 2025, its largest moves.
• Ani Pharmaceuticals' Non Operating Income stood at -$42000.0 in 2022, then grew by 21.43% to -$33000.0 in 2023, then slumped by 4075.76% to -$1.4 million in 2024, then soared by 161.68% to $850000.0 in 2025, then slumped by 176.59% to -$651000.0 in 2026.
• The last three Non Operating Income figures came in at -$651000.0 (Q1 2026), $850000.0 (Q4 2025), and -$853000.0 (Q3 2025), per Business Quant data.